Nov. 24 (Bloomberg) -- Advent Venture Partners LLP, a London-based investment firm, has raised $120 million for its first life science fund.
The fund will invest in early- to mid-stage life science companies in the U.K., Europe and U.S. and will be managed by partners Shahzad Malik and Raj Parekh, Advent said in an e-mailed statement today.
Advent has invested in PowderMed, which was bought by Pfizer Inc.; Thiakis, which was purchased by Wyeth, and Respivert, which was bought by Johnson & Johnson.
To contact the reporter on this story: Chris Kay in London at email@example.com
To contact the editors responsible for this story: Phil Serafino at firstname.lastname@example.org